RDCRN

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Research, Software, University, Infectious Diseases, Education, Hospitals, Health Technology, Genetics, Health Insurance, Data Management, Science, Technology, Clinical Trials, Biotechnology, FDA, Insurance, Health, Professional Services, IOT (Internet of Things), Data Analytics, White House, Federal Government, Practice Management, Managed Care, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Pancreatic disease, Consolidated, Patient, Conditional sentence, Optum, Health information management, Food and Drug Administration, Geography, NPF, RWE, Internet of things, Openclinica, DNA, Policy, Electronic health record, NIH, City, Privacy, CMS, Food, Organization, Prevalence, Federation, Internet, Cancer, Drug development, IQVIA, Evidence-based medicine, RDCRN, Type, Data science, Caregiver, Public health surveillance, Government agency, Registry, EHR, CDC, National Institutes of Health, Bangladesh Technical Education Board, Medicare, Collection, Medical device

The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.

Key Points: 
  • The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.
  • Patient registry software could facilitate data sharing and analysis among these entities, leading to increased adoption
    The patient registry software market in the USA is a part of the broader healthcare information technology sector.
  • Key players in the USA patient registry software market includes IQVIA, Dacima Software, OpenClinica, FIGmd, Dendrite Clinical Systems and various universities conducting medical clinical studies.
  • As technology & data science continue to evolve, the patient registry software market is likely to incorporate more advanced analytics techniques.

Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 6, 2022
Genetics, Health, Medical Devices, NIH, Degenerative disease, Cushing's syndrome, Disorder, NGS, Revenue, Projection, Disease, Diagnosis, Patient, Prevalence, Rare Diseases Clinical Research Network, Research, Data collection, Cros, Government, Growth, Genetic testing, RDCRN, USD, Registry, Agriculture, Pharmaceutical industry, Antibiotics, Vaccine

The "Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global rare disease genetic testing market size is expected to reach USD 2,414.90 million by 2030 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The publisher has segmented the rare disease genetic testing market report based on disease type, technology, specialty, end-use, and regions:
    Rare Disease Genetic Testing, Disease Type Outlook (Revenue - USD Million, 2018 - 2030)

Global Rare Disease Genetic Testing Market Report 2022: Ongoing Conferences to Raise Awareness About Rare and Ultra-Rare Conditions to Boost Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 19, 2022
Research, Mental Health, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Science, Oncology, Other Science, Health policy, Rare Disease Day, Neurology, Canadian Organization for Rare Disorders, National, Genetic testing, Adoption, Degenerative disease, Incidence, CORD, CVD, RDCRN, Sclerosis, Registry, Organization, Learning, Growth, Industry, Rare Diseases Clinical Research Network, Lists of diseases, USD, Patient, Investment, Cancer, Disorder, CLIA, Diagnosis, NGS, Research, Awareness, PCR, NIH, Disease, Disease management, CAGR, Vaccine, Pharmaceutical industry, Technology

The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to this report.

Key Points: 
  • The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to this report.
  • Effective regulatory plans to combat rare disease is one of the key drivers of the industry.
  • Ongoing conferences to raise awareness about rare and ultra-rare conditions are anticipated to boost the adoption of diagnostic kits and services.
  • Furthermore, the lack of awareness among patients and families about diagnosis and genetic testing has further impeded the industry's growth.

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

Retrieved on: 
Monday, February 28, 2022
Rubius, Therapy, SANA, Office of Rare Diseases Research, Health, National Center for Advancing Translational Sciences, Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Growth, Degenerative disease, RNA, Informatics, NIH, Investment, RDCRN, Georgetown University School of Medicine, Language, National Institutes of Health, NCATS, David Berry (inventor), Biology, Center for Drug Evaluation and Research, Drug development, Flagship Pioneering, MRNA, Center, Disease, RNA transfection, Review, Food, Rare Diseases Clinical Research Network, Multimedia, Motivation, National, CDER, FDA, Nasdaq, MBA, Ecosystem, Flagship, Internal medicine, Doctor of Philosophy, Georgetown University Medical Center, Policy, Pharmaceutical industry, Medical device, Research

Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs.

Key Points: 
  • Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs.
  • "We are thrilled she has joined our team to lead Alltrna's strategy for regulatory and medical research as we leverage tRNA biology as a platform approach to treat many diseases with a single medicine."
  • "As a therapeutic mechanism, tRNA has this unique potential to treat thousands of different diseases with a precision medicine approach.
  • During her tenure at ORDR, Dr. Pariser oversaw the Rare Diseases Clinical Research Network (RDCRN), a network of rare diseases research consortia focusing on research programs into more than 200 different rare diseases and other research programs.